Cancer Biomarkers Market Size Worth US$ ~31.7 billion by 2030: Exclusive Report by Growth Plus Reports

NEW YORK, July 22, 2022 /PRNewswire/ -- The global cancer biomarkers market size was pegged at ~US$ 12.2 billion in 2021. The market is expected to clock US$ ~31.7 billion by 2030, to grow at a CAGR of 11.2% between the forecast period. All information is portrayed in the latest report published by Growth Plus Reports.  Report Title "Cancer Biomarkers Market by Type (Genomic Biomarkers, Proteomic Biomarkers and Transcriptomic Biomarkers), Profiling Technology (Omic Technologies, Imaging Technologies and Immunoassays), Application (Diagnostics, Drug Discovery & Development, and Personalized Medicine), Cancer Type (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Blood Cancer and Skin Cancer) – Global Outlook & Forecast 2022-2030"

Growth Factors

The global cancer biomarkers market is mainly driven by the rising incidence of various types of cancers, increasing R&D activities, and widening applications of biomarkers in cancer diagnostics and drug discovery.

Furthermore, the growing investments to boost the discovery and development of cancer diagnostics and treatment, and the rising trend of personalized medicines are other factors contributing to the market growth. The prominent players are progressively implementing several growth strategies such as collaborative initiatives with various organizations, government bodies, and companies to propagate research activities and thereby come up with innovative products in the market.

Cancer is major cause of death worldwide. According, to the World Health Organization in 2020 around 10 million people died because of cancer. The most common cancers are prostate cancer, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, breast cancer, lung bronchus cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma,  thyroid cancer, and liver cancer. In 2020 around 606,520 people will die from cancer in the United States and almost 1,806,590 new cases of cancer diagnosed.

The global cancer biomarkers market has been analyzed from five different perspectives–Type, Profiling Technology, Application, Cancer Type, and Region.

Download Exclusive Sample of Report @ https://growthplusreports.com/inquiry/request-sample/cancer-biomarkers-market/7712

Excerpts from 'Competitive Landscape'

The prominent players operating in the global cancer biomarkers market are

• Qiagen NV
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc
• General Electric Company
• Abbott Laboratories Inc
• Agilent Technologies, Inc
• Bio-Rad Laboratories, Inc
• Illumina, Inc
• bioMérieux SA
• Myriad Genetics, Inc
• Among others

Excerpts from 'by Type Segmentation'

Based on type, the cancer biomarkers market has been segmented into:-

• Genomic Biomarkers
• Proteomic Biomarkers
• Transcriptomic Biomarkers
• Others (Epigenomic Biomarkers, Metabolomic Biomarkers, Etc.)

Technological advancement in genome clinical diagnostics for cancer biomarkers is one of the important factors for the growth of this market; rise in the cases of hereditary cancer is also fueling the cancer biomarkers demand. The genomic biomarkers dominated the market with the largest share owing to the technological advancements and widespread adoption of genetic biomarkers for the early diagnosis of cancer owing to its greater speed and accuracy in detection. Transcriptomics biomarkers also showed market growth owing to increasing demand for personalized medicine, rise in applications of RNA sequencing, and development of new transcriptomics products by key players. 

Excerpts from 'By Profiling Technology Segmentation'

The global cancer biomarkers market has been segmented majorly into four distinct categories depending on profiling technology, viz.

• Omic Technologies
• Imaging Technologies
• Immunoassays
• Others (Cytogenetics, Bioinformatics, Etc.)

The omic technologies dominated the market with the largest share in 2021. Omics technologies are high throughput techniques that enables the fast discovery of candidate biomarkers. It allows to gather large amounts of data about the human genome, proteins, and metabolites. This technology is expected to co- evolve with biomarker-based precision medicine leading to better patient care. For instance, in June 2022, Research scientists and statisticians from UC San Francisco introduced improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The researchers found that by combining predictive biomarkers to create a response predicting breast cancer subtypes, these subtypes can then be matched to the most effective modern treatments.

Excerpts from 'By Region Segmentation'

The global cancer biomarkers market has been segmented into:-

• North America
• Europe
• Asia Pacific
• Rest of the World (RoW)

North America commanded the largest share of the global cancer biomarkers market in 2021. Factors such as advanced infrastructure, well-structured government policy, a large number of R&D activities associated with biomarkers, growing prevalence of the various types of cancer, and greater adoption of biomarkers technologies for personalized medicine and drug discovery & development are driving the regional market growth.  Asia Pacific is also projected to be the fastest growing cancer biomarkers market. The high growth of the region is mainly attributed to rising clinical cases of cancers, developing healthcare infrastructure, and government policyIn June 2022 Nonagen Bioscience received CE marketing for its oncuria Immunoassay for bladder cancer. Oncuria is the first-of-its-kind multiplex urine test for the quantitative detection of 10 biomarkers in urine that are associated with the presence of bladder cancer. Oncuria now bears the CE marking and is registered under the EU In Vitro Diagnostic Directive (IVDD), EU Directive 98/79/EC, which allows Nonagen to sell the diagnostic tool in the European market.

Ask here for more customization study@ https://growthplusreports.com/inquiry/customization/cancer-biomarkers-market/7712

Report Scope & Segmentation:

Table of Content:

1. INTRODUCTION
1. Market Ecosystem
2. Geographic Scope
3. Timeline Under Consideration
1. Historical Years – 2020
2. Base Year – 2021
3. Forecasted Years – 2022 to 2030
4. Currency Used in the Report
2. RESEARCH METHODOLOGY 
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources 
2. Primary Sources 
4. Market Estimation Approach
1. Bottom Up 
2. Top Down 
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Technological Advancement
3. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
1. Drivers
2. Restraints/Challenges
3. Opportunities

TOC Continued…..

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Speak to Our Expert: https://growthplusreports.com/inquiry/speak-analyst/cancer-biomarkers-market/7712

About Us:

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

Contact:
Manan Sethi
Director, Market Insights
Email: [email protected]
Phone no: +91 96545 76783
Web: https://growthplusreports.com/ 
Follow Us: LinkedIn | Twitter

Logo : https://mma.prnewswire.com/media/1671244/Growth_Plus_Reports_Logo.jpg 

SOURCE Growth Plus Reports

21%

more press release views with 

Request a Demo